Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.

Oncotarget

Panek WK, Kane JR, Young JS, Rashidi A, Kim JW, Kanojia D, Lesniak MS.
PMID: 29179527
Oncotarget. 2017 Sep 11;8(51):89391-89405. doi: 10.18632/oncotarget.20810. eCollection 2017 Oct 24.

Glioblastoma is a highly aggressive malignant brain tumor with a poor prognosis and the median survival 14.6 months. Immunomodulatory proteins and oncolytic viruses represent two treatment approaches that have recently been developed for patients with glioblastoma that could extend...

Cite
Panek WK, Kane JR, Young JS, et al. Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma. Oncotarget. 2017;8(51):89391-89405doi: 10.18632/oncotarget.20810.
Panek, W. K., Kane, J. R., Young, J. S., Rashidi, A., Kim, J. W., Kanojia, D., & Lesniak, M. S. (2017). Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma. Oncotarget, 8(51), 89391-89405. https://doi.org/10.18632/oncotarget.20810
Panek, Wojciech K, et al. "Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma." Oncotarget vol. 8,51 (2017): 89391-89405. doi: https://doi.org/10.18632/oncotarget.20810
Panek WK, Kane JR, Young JS, Rashidi A, Kim JW, Kanojia D, Lesniak MS. Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma. Oncotarget. 2017 Sep 11;8(51):89391-89405. doi: 10.18632/oncotarget.20810. eCollection 2017 Oct 24. PMID: 29179527; PMCID: PMC5687697.
Copy Download .nbib Format: NLM
Programmable ROS-Mediated Cancer Therapy via Magneto-Inductions.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Wu J, Ning P, Gao R, Feng Q, Shen Y, Zhang Y, Li Y, Xu C, Qin Y, Plaza GR, Bai Q, Fan X, Li Z, Han Y, Lesniak MS, Fan H, Cheng Y.
PMID: 32596106
Adv Sci (Weinh). 2020 May 09;7(12):1902933. doi: 10.1002/advs.201902933. eCollection 2020 Jun.

Reactive oxygen species (ROS), a group of oxygen derived radicals and derivatives, can induce cancer cell death via elevated oxidative stress. A spatiotemporal approach with safe and deep-tissue penetration capabilities to elevate the intracellular ROS level is highly desirable...

Cite
Wu J, Ning P, Gao R, et al. Programmable ROS-Mediated Cancer Therapy via Magneto-Inductions. Adv Sci (Weinh). 2020;7(12):1902933doi: 10.1002/advs.201902933.
Wu, J., Ning, P., Gao, R., Feng, Q., Shen, Y., Zhang, Y., Li, Y., Xu, C., Qin, Y., Plaza, G. R., Bai, Q., Fan, X., Li, Z., Han, Y., Lesniak, M. S., Fan, H., & Cheng, Y. (2020). Programmable ROS-Mediated Cancer Therapy via Magneto-Inductions. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 7(12), 1902933. https://doi.org/10.1002/advs.201902933
Wu, Jiaojiao, et al. "Programmable ROS-Mediated Cancer Therapy via Magneto-Inductions." Advanced science (Weinheim, Baden-Wurttemberg, Germany) vol. 7,12 (2020): 1902933. doi: https://doi.org/10.1002/advs.201902933
Wu J, Ning P, Gao R, Feng Q, Shen Y, Zhang Y, Li Y, Xu C, Qin Y, Plaza GR, Bai Q, Fan X, Li Z, Han Y, Lesniak MS, Fan H, Cheng Y. Programmable ROS-Mediated Cancer Therapy via Magneto-Inductions. Adv Sci (Weinh). 2020 May 09;7(12):1902933. doi: 10.1002/advs.201902933. eCollection 2020 Jun. PMID: 32596106; PMCID: PMC7312334.
Copy Download .nbib Format: NLM
Current state of clinical trials in breast cancer brain metastases.

Neuro-oncology practice

Fares J, Kanojia D, Cordero A, Rashidi A, Miska J, Schwartz CW, Savchuk S, Ahmed AU, Balyasnikova IV, Cristofanilli M, Gradishar WJ, Lesniak MS.
PMID: 31555454
Neurooncol Pract. 2019 Sep;6(5):392-401. doi: 10.1093/nop/npz003. Epub 2019 Feb 11.

BACKGROUND: Breast cancer brain metastases (BCBM) are the final frontier in neuro-oncology for which more efficacious therapies are required. In this work, we explore clinical trials in BCBM, and determine the shortcomings in the development of new BCBM therapies...

Cite
Fares J, Kanojia D, Cordero A, et al. Current state of clinical trials in breast cancer brain metastases. Neurooncol Pract. 2019;6(5):392-401doi: 10.1093/nop/npz003.
Fares, J., Kanojia, D., Cordero, A., Rashidi, A., Miska, J., Schwartz, C. W., Savchuk, S., Ahmed, A. U., Balyasnikova, I. V., Cristofanilli, M., Gradishar, W. J., & Lesniak, M. S. (2019). Current state of clinical trials in breast cancer brain metastases. Neuro-oncology practice, 6(5), 392-401. https://doi.org/10.1093/nop/npz003
Fares, Jawad, et al. "Current state of clinical trials in breast cancer brain metastases." Neuro-oncology practice vol. 6,5 (2019): 392-401. doi: https://doi.org/10.1093/nop/npz003
Fares J, Kanojia D, Cordero A, Rashidi A, Miska J, Schwartz CW, Savchuk S, Ahmed AU, Balyasnikova IV, Cristofanilli M, Gradishar WJ, Lesniak MS. Current state of clinical trials in breast cancer brain metastases. Neurooncol Pract. 2019 Sep;6(5):392-401. doi: 10.1093/nop/npz003. Epub 2019 Feb 11. PMID: 31555454; PMCID: PMC6753353.
Copy Download .nbib Format: NLM
The Dynamic Interactions between Nanoparticles and Macrophages Impact Their Fate in Brain Tumors.

Small (Weinheim an der Bergstrasse, Germany)

Feng Q, Xu X, Wei C, Li Y, Wang M, Lv C, Wu J, Dai Y, Han Y, Lesniak MS, Fan H, Zhang L, Cheng Y.
PMID: 34643042
Small. 2021 Dec;17(49):e2103600. doi: 10.1002/smll.202103600. Epub 2021 Oct 12.

Functional nanomaterials such as iron oxide nanoparticles have been extensively explored for the diagnosis and treatment of central nervous system diseases. However, an insufficient understanding of the comprehensive nanomaterial-biological interactions in the brain hinders the nanomaterials from meeting the...

Cite
Feng Q, Xu X, Wei C, et al. The Dynamic Interactions between Nanoparticles and Macrophages Impact Their Fate in Brain Tumors. Small. 2021;17(49):e2103600doi: 10.1002/smll.202103600.
Feng, Q., Xu, X., Wei, C., Li, Y., Wang, M., Lv, C., Wu, J., Dai, Y., Han, Y., Lesniak, M. S., Fan, H., Zhang, L., & Cheng, Y. (2021). The Dynamic Interactions between Nanoparticles and Macrophages Impact Their Fate in Brain Tumors. Small (Weinheim an der Bergstrasse, Germany), 17(49), e2103600. https://doi.org/10.1002/smll.202103600
Feng, Qishuai, et al. "The Dynamic Interactions between Nanoparticles and Macrophages Impact Their Fate in Brain Tumors." Small (Weinheim an der Bergstrasse, Germany) vol. 17,49 (2021): e2103600. doi: https://doi.org/10.1002/smll.202103600
Feng Q, Xu X, Wei C, Li Y, Wang M, Lv C, Wu J, Dai Y, Han Y, Lesniak MS, Fan H, Zhang L, Cheng Y. The Dynamic Interactions between Nanoparticles and Macrophages Impact Their Fate in Brain Tumors. Small. 2021 Dec;17(49):e2103600. doi: 10.1002/smll.202103600. Epub 2021 Oct 12. PMID: 34643042.
Copy Download .nbib Format: NLM
A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.

Molecular therapy oncolytics

Kim JW, Miska J, Young JS, Rashidi A, Kane JR, Panek WK, Kanojia D, Han Y, Balyasnikova IV, Lesniak MS.
PMID: 28573184
Mol Ther Oncolytics. 2017 May 06;5:97-104. doi: 10.1016/j.omto.2017.05.001. eCollection 2017 Jun 16.

Oncolytic virotherapy is a treatment approach with increasing clinical relevance, as indicated by the marked survival benefit seen in animal models and its current exploration in human patients with cancer. The use of an adenovirus vector for this therapeutic...

Cite
Kim JW, Miska J, Young JS, et al. A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model. Mol Ther Oncolytics. 2017;5:97-104doi: 10.1016/j.omto.2017.05.001.
Kim, J. W., Miska, J., Young, J. S., Rashidi, A., Kane, J. R., Panek, W. K., Kanojia, D., Han, Y., Balyasnikova, I. V., & Lesniak, M. S. (2017). A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model. Molecular therapy oncolytics, 597-104. https://doi.org/10.1016/j.omto.2017.05.001
Kim, Julius W, et al. "A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model." Molecular therapy oncolytics vol. 5 (2017): 97-104. doi: https://doi.org/10.1016/j.omto.2017.05.001
Kim JW, Miska J, Young JS, Rashidi A, Kane JR, Panek WK, Kanojia D, Han Y, Balyasnikova IV, Lesniak MS. A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model. Mol Ther Oncolytics. 2017 May 06;5:97-104. doi: 10.1016/j.omto.2017.05.001. eCollection 2017 Jun 16. PMID: 28573184; PMCID: PMC5443908.
Copy Download .nbib Format: NLM
Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Chastkofsky MI, Pituch KC, Katagi H, Zannikou M, Ilut L, Xiao T, Han Y, Sonabend AM, Curiel DT, Bonner ER, Nazarian J, Horbinski CM, James CD, Saratsis AM, Hashizume R, Lesniak MS, Balyasnikova IV.
PMID: 33272983
Clin Cancer Res. 2021 Mar 15;27(6):1766-1777. doi: 10.1158/1078-0432.CCR-20-1499. Epub 2020 Dec 03.

PURPOSE: Diffuse intrinsic pontine glioma (DIPG) is among the deadliest of pediatric brain tumors. Radiotherapy is the standard-of-care treatment for DIPG, but offers only transient relief of symptoms for patients with DIPG without providing significant survival benefit. Oncolytic virotherapy...

Cite
Chastkofsky MI, Pituch KC, Katagi H, et al. Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma. Clin Cancer Res. 2020;27(6):1766-1777doi: 10.1158/1078-0432.CCR-20-1499.
Chastkofsky, M. I., Pituch, K. C., Katagi, H., Zannikou, M., Ilut, L., Xiao, T., Han, Y., Sonabend, A. M., Curiel, D. T., Bonner, E. R., Nazarian, J., Horbinski, C. M., James, C. D., Saratsis, A. M., Hashizume, R., Lesniak, M. S., & Balyasnikova, I. V. (2021). Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1766-1777. https://doi.org/10.1158/1078-0432.CCR-20-1499
Chastkofsky, Michael I, et al. "Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,6 (2021): 1766-1777. doi: https://doi.org/10.1158/1078-0432.CCR-20-1499
Chastkofsky MI, Pituch KC, Katagi H, Zannikou M, Ilut L, Xiao T, Han Y, Sonabend AM, Curiel DT, Bonner ER, Nazarian J, Horbinski CM, James CD, Saratsis AM, Hashizume R, Lesniak MS, Balyasnikova IV. Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma. Clin Cancer Res. 2021 Mar 15;27(6):1766-1777. doi: 10.1158/1078-0432.CCR-20-1499. Epub 2020 Dec 03. PMID: 33272983; PMCID: PMC7956061.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries